Login to Your Account

Biotest, Abbott Target Crowded RA Space as Part of $480M Deal

By Jennifer Boggs

Wednesday, June 22, 2011
German firm Biotest AG is getting $85 million up front in an autoimmune disease deal, with new partner Abbott hoping that the mechanism for midstage candidate BT-061 will be enough to differentiate it in crowded markets such as rheumatoid arthritis (RA) and psoriasis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription